Abstract Library

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Linder Ekberg K,

Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,

#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors

Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Galler M, Schatka I, Buch F, Bluemel S, Jann H,

Keywords: Lu-177-DOTATOC, PRRT, NET, dosimetry, SPECT/CT, Quantification,

#2838 Accidental Injection of Unlabeled Lu-177 Caused Catastrophic Consequences in Patients with Neuroendocrine Tumor

Introduction: Since Lu-177 DOTATATE treatment is not approved in South Korea, patients with neuroendocrine tumors were sent to Germany and Malaysia for the treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kang K, Song Y, Kwon T, Ha W, Jin Y,

Keywords: radiation accident, PRRT, neuroendocrine tumor,

#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,

#2753 Risk of PRRT-Associated Bowel Obstruction in Patients with Mesenteric/Peritoneal Disease and Potential Role of Corticosteroids in Treatment

Introduction: Although radiation-induced mesenteritis or peritonitis can potentially exacerbate risk of bowel obstruction, there are no data in the literature on incidence of intestinal obstruction related to peptide receptor radiotherapy (PRRT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Al-Toubah T, El-Haddad G, Pelle E, Strosberg J,

Keywords: PRRT, Lutetium-dotatate, Bowel obstruction, Peritoneal carcinomatosis, Steroids,